Amedi.sk
Dovoľujeme si Vás upozorniť, že naša web stránka
je určená iba pre odbornú lekársku verejnosť.
Časopis Clinical urology – Článok Suboptimal response in patients with metastatic castration-resistant prostate cancer and presence of the androgen receptor splice variant AR-V7 treated with abiraterone and enzalutamide

Clinical urology

Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
1336-7579
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Clinical urology
Clinical urology
Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
Predplatné
Téma: Urological oncology

Suboptimal response in patients with metastatic castration-resistant prostate cancer and presence of the androgen receptor splice variant AR-V7 treated with abiraterone and enzalutamide

Ján Kliment, Katarína Baluchová, Marián Grendár, Boris Eliáš, Roman Mráz, Peter Čech, Klaudia Holečková, Ján Kliment Jr., Henrieta Drobková

Objective: The study aimed to evaluate the association between the presence of the androgen receptor splice variant 7 (AR-V7) in circulating tumour cells (CTC) and the efficacy of androgen receptor inhibitors abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Material and methods: CTC were isolated using the AdnaTest® kit in 104 samples of peripheral blood from patients with mCRPC. The presence of AR-V7 was determined after reverse transcription of the mRNA into cDNA by a polymerase chain reaction and subsequently verified by Sanger sequencing. Levels of prostate-specific antigen (PSA) were measured before treatment at regular intervals during treatment with abiraterone or enzalutamide. A 2- sample test for equality of proportions with continuity was used to compare the rate of best PSA response to treatment between individual groups of patients.
Results: In the overall evaluated cohort of 75 men, we detected the presence of CTC in 36 men (48%). We found the presence of the AR-V7 in CTC in 10 patients (27.78%). When we examined the best PSA response to treatment, we found that the relative number of patients with the PSA decrease ≥ 50% was statistically significantly higher in the group of patients without detected CTC compared to the group of patients with detected CTC expressing the AR-V7 (p=0.004).
Conclusion: The study results indicate that the presence of the AR-V7 in CTC affects the efficacy of treatment with abiraterone and enzalutamide in patients with mCRPC.

prostate cancer, circulating tumour cells, androgen receptor splice variant AR-V7, abiraterone, enzalutamide
Klin urol 2020; 16 (1): 6 – 12

Ročník 2020  Témy časopisu Clinical urology 1 / 2020

Urological oncology

Ján Kliment, Katarína Baluchová, Marián Grendár, Boris Eliáš, Roman Mráz, Peter Čech, Klaudia Holečková, Ján Kliment Jr., Henrieta Drobková
Ján Ľupták, Ján Šulgan, Boris Eliáš, Ján Kliment, sen., Ján Švihra, sen., Ján Kliment jr., Igor Sopilko, Roman Tomaškin, Anna Rašková, Pavol Slávik

Funkcional urology

Magdaléna Hagovská, Ján Švihra, Ján Breza jr., Jozef Dubravický, Marek Vargovčák
Magdaléna Hagovská, Ján Švihra, Ján Breza jr., Jozef Dubravický, Marek Vargovčák
Jozef Marenčák
Michal Kmak

Case studies

Matúš Richnavský, Vincent Nagy, Martin Hrivňák, Ľubomír Lachváč, Andrej Bӧӧr
Vincent Nagy, Hedviga Wagnerová, Dana Nagyová, Helena Baumöhlová
3 1
3 1
3 1
3 2 1
3 1
3 1
2 1
2 1
2 1
3 2 1
3 2 1
2 1
3 2 1
3 2 1
1
Nie sú dostupné žiadne voľne dostupné články
CHAIRMAN OF THE EDITORIAL BOARD
prof. MUDr. Ján Kliment, CSc.

MEMBERS OF THE EDITORIAL BOARD
prof. Andrzej Borówka, M.D., PhD.
prof. MUDr. Ján Breza, DrSc.
prof. MUDr. Peter Bujdák, PhD.
prof. MUDr. Tomáš Hanuš, DrSc.
doc. MUDr. Ladislav Jarolím, CSc.
doc. MUDr. Ján Ľupták, PhD.
doc. MUDr. Jozef Marenčák, PhD.
doc. MUDr. Ivan Minčík, PhD.
prof. MUDr. Dalibor Ondruš, DrSc.
prof. Imre Romics, M.D., PhD.
doc. MUDr. Vladimír Študent, PhD.
prof. MUDr. Ján Švihra, PhD.
prof. MUDr. Ladislav Valanský, PhD.
doc. MUDr. František Záťura, PhD.
MUDr. Peter Zvara, PhD.

PROFESSIONAL EDITOR
prof. MUDr. Ján Švihra, PhD.

EDITOR-IN-CHIEF
Ing. Danica Paulenová
e-mail: paulenova@amedi.sk

GRAPHIC LAYOUT AND TYPESETTING
Lucia Vecseiová
e-mail: dtp@amedi.sk

MARKETING MANAGER
Ing. Dana Chodasová
mobil: 0903 224 625
e-mail: marketing@amedi.sk

ECONOMY AND SUBSCRIPTIONS
Ing. Mária Štecková
telefón: 02/55 64 72 48
mobil: 0911 117 949
e-mail: ekonom@amedi.sk

LANGUAGE PROOFREADING
Mgr. Eva Doktorová

PROOFREADING OF ENGLISH TEXTS
Mgr. Jana Bábelová
SECTIONS

OVERVIEW PAPERS
The latest knowledge on disease and disease groups aetiology, pathogenesis, diagnoses and therapy. Maximum extent is 7 pages of text (font ARIAL or TIMES, font size 12, line spacing 1.5). In case of more extensive theme elaboration it is possible to divide the paper to several parts after agreement with editorial office.

ORIGINAL PAPERS
Structuring: introduction, clinical group and methods, results, discussion, conclusion, bibliography

DIAGNOSTIC AND THERAPEUTICAL ALGORITHMS
Diagnosis and therapy processed into tables and schemes, with minimum text, with emphasis on conciseness and clarity.

CASE STUDY
Maximum extent is 3 pages. Structuring: summary, case study, conclusion, bibliography.

MISCELLANEOUS
Reaction to overview articles, news in the field of diagnostics, therapy, trial results (maximum 3 pages), reports from professional events, abstracts from scientific work published abroad, not older than 1 year. Maximum extend is 1 page. Title of the paper in Slovak/Czech, authors, workplace, then title of the paper in English with full citation.


MANUSCRIPT ELABORATION

Write the paper on computer in any common text editor.
write full length of lines (do not use ENTER at the end of a line)
- do not arrange text into columns
- do not do page make-up, put tables at the end of the paper
- distinguish precisely numbers 1, 0 and letters l, O
- use always parentheses ( )
- explain abbreviations always when first used


MANUSCRIPT REQUIREMENTS

1. An accurate paper title, names and surnames of all authors including titles, authors` workplace. The first author address including the phone number, fax and e-mail address.
2. Summary - structured abstract: goal of work, material and methods (do not state the name of the workplace), results, conclusion
3. Key words - in the extent of 3-6.
Write in 1st or 3rd person singular or plural (unify according the type of an article).
4. English translation: the title of the paper, summary, key words 5. Text
If you insert pictures into a document, send also their original files in "jpg" format, create graphs in Excel and send also their original files. If you send photo documentation via post office, please, send just high-class originals. Mark each original by a number, under which it is mentioned in the text. Write in 1st or 3rd person singular or plural (unify according the type of an article). In the text do not use highlighting of the text as e.g. underlined text, bold, with exception of titles, references to pictures, tables, graphs.

6. Bibliography
Citations are numbered chronologically in bold, references in the text are stated by the number of citations in parentheses.
Citation means in general: the surname of the author (authors), title of the work, year of issuing, volume, pages.
Do not use "ét al.", but state all authors.

Examples of citations:
1. Shaheen NJ, Crosby NA, Bozymski EM, et al. Is there publication bias in the reporting cancer risk in Barrett´ esophagus? Gastroenterology 2000; 119: 333-338.
2. Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
3. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
4. Jurkovičová O, Spitzerová H, Cagáň S. Komorové arytmie a náhla srdcová smrť pri akútnom infarkte myokardu. Bratisl Lek Listy 1997; 98: 379-389.
5. Osborne BE. The electrocardiogram of the rat. In: Budden R, Detweiler DK, Zbinden G. The rat electrocardiogram in pharmacology and toxicology. Oxford: Pergamon Press 1981:15-27.

Do not use dots after first names in citations. Do not use colon but dot after names of authors. Use semi-colon after the year of publishing, colon is before pages.

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are reviewed.

Which of following factors is not related to rosacea?
a. genetic predisposition
b. Scandinavian origin
c. propionibacterium acnes
d. endothelial growth factor

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are reviewed.

All published papers are paid.

Send contributions in the e-mail to the address: paulenova@amedi.sk
Period 3x per year
1336-7579
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Clinical urology
Clinical urology
Postgraduate scientific medical journal. Magazine Slovak Association of Urology.
Period 3x per year
Predplatné